FDA's Hamburg declares no one can "inspect world on its own" for poor quality medicines
This article was originally published in Scrip
Executive Summary
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.